TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05251688

Intervention type: OTHER
Group type: OTHER
Intervention: Cryoanalgesia
Description: On the first day of the study, the PI met the participants and assessed their level of consciousness using the Modified Glasgow Coma Scale to ensure that they were unconscious and reviewed the medical records to collect their sociodemographic data. After that, the participants received routine care before the arterial puncture. The PI assessed their pain scores during the puncture.~In the second meeting (on the same day or the following day), the PI prepared the ice packs by crushing small pieces of ice and wrapping them in smooth gauze to avoid skin damage and moisture in the puncture area. Before the arterial puncture, the ice pack was applied over the selected puncture site (radial, brachial, or femoral artery) for 5 minutes in addition to the routine care. After removing the ice pack, the nurse palpated the artery, wiped of the residue of ice vapor present on the skin, and took the arterial blood sample. During the puncture, the PI assessed the participants' pain scores.
Study: NCT01354795

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1.EUS-FNA with or without suction
Description: During EUS-FNA of the peri-pancreatic mass was performed, with or without self-retracting 10-mL syringe applied.
Study: NCT00700817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, minimum 1500 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, minimum 1500 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.8 mg once daily, subcutaneous (under the skin) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.8 mg once daily, subcutaneous (under the skin) injection
Study: NCT01354795

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2.Pushing the stylet or injecting air
Description: EUS-FNA specimen is expelled from a needle with pushing the stylet or injecting air into the needle
Study: NCT01184664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Varenicline + nicotine patch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Varenicline + placebo patch
Study: NCT02215148

Intervention type: DRUG
Intervention: Tolvaptan
Study: NCT04272203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-184
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-184
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-184
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-184
Description: Intravenous (IV) infusion
Study: NCT01333072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: The starting dosage will be 2.0 mg/day. The dosage will be allowed to increase to 5.0 mg/day on day 4 and can be increased thereafter as judged clinically appropriate until the maximum dosage of 15 mg/day. The dosage will only be increased in 5.0 mg intervals. No dosage adjustments will be allowed for either drug after 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Children weighing 20-45 kg will receive an initial dose of 0.5 mg daily that will be increased to twice daily on day 4 (morning and bedtime). The dosage will be gradually increased in 0.5 mg increments to a maximum dose of 2.5 mg per day (1.0 mg in the morning and 1.5 mg at bedtime) by the fourth treatment week. A slightly accelerated dosage will be allowed for children who weigh more than 45 kg for a maximum dosage of 3.5 mg /day (McCracken et al 2002).
Study: NCT01453621

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized clinical decision support
Description: Intervention sites will receive decision support regarding whether patient meets very low risk criteria for clinically-important traumatic brain injury based on the PECARN prediction rules.
Study: NCT03074864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Subjects receive erlotinib tablet 150mg orally once daily, after 12 weeks of induction phase, local radiotherapy is intercalated, and followed by 24-week erlotinib maintenance phase. At the end of maintenance, the subjects enter into the follow-up period.
Study: NCT03721302

Intervention type: OTHER
Intervention: Main study clinical sepsis
Description: No intervention-Observational study

Intervention type: OTHER
Intervention: Main study clinical sepsis
Description: No intervention-Observational study

Intervention type: OTHER
Intervention: Microbiology sub study
Description: Analysis of Bacterial isolates
Study: NCT02430805

Intervention type: OTHER
Group type: OTHER
Intervention: dna extraction and genotyping
Description: blood and urine sample
Study: NCT01184664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: All participants will receive a standard dose of varenicline (12 weeks).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline
Description: All participants will receive a standard dose of varenicline (12 weeks).
Study: NCT05929105

Intervention type: PROCEDURE
Intervention: artificial intelligence (AI)-assisted three-dimensional preoperative planning technology
Description: In the AI planning group, AI was used to assist in the 3D planning to complete the preoperative design. Preoperative planning was performed by two experienced surgeons and without the chief physician to ensure that the results of the preoperative planning did not affect the selection of intraoperative procedures and prosthesis size.

Intervention type: OTHER
Intervention: X-ray film template for 2D planning
Description: A traditional X-ray film template was used to complete the preoperative design in the traditional planning group. The position and size of the prosthesis, the level of femoral neck osteotomy, the length of the LLs and the restoration of eccentricity were estimated by X-ray. A plastic template provided by the manufacturer was used to take the line of the lower edge of the teardrop on both sides as the horizontal reference line, and the acetabular template was placed at 40 abduction on the inner edge of the teardrop so that the lower edge of the acetabular cup was adjacent to the teardrop. An appropriate type of acetabular component was selected to fill the acetabulum and maintain coverage, and the femoral component that best matched the femoral medullary cavity was chosen. The height of the osteotomy was determined, and the planning model was recorded after the surgeons were happy with the placement and outcome.
Study: NCT01352533

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Running polypropylene closure
Description: Half of every wound will be closed with Standard of Care running polypropylene sutures

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue Adhesive (Derma-Bond)
Description: Approximately half of wounds will be randomized to be closed with tissue adhesive.
Study: NCT02054013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatic artery embolization

Intervention type: PROCEDURE
Group type: OTHER
Intervention: monopolar transurethral prostatectomy
Study: NCT02264535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1mg/ml Ginkgolides Meglumine Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1mg/ml Ginkgolides Meglumine Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5mg/ml Ginkgolides Meglumine Injection
Study: NCT00362830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinflunine + ixabepilone
Description: solution for injection, IV, vinflunine: 250 to 320 mg/m2 + ixabepilone: 30 to 40 mg/m2, every 3 wks, variable duration
Study: NCT02358850

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norco (Hydrocodone and Acetaminophen)
Description: Norco (Hydrocodone and Acetaminophen) 5/325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN (as needed) pain following Tonsillectomy for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Percocet (Oxycodone and Acetaminophen)
Description: Percocet (Oxycodone and Acetaminophen) 5/325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dilaudid (hydromorphone)
Description: Dilaudid (hydromorphone) 2 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tylenol (Acetaminophen)
Description: Tylenol (Acetaminophen) 325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
Study: NCT00965770

Intervention type: DEVICE
Intervention: Intrauterine device (IUD)
Description: Women choosing to have an intrauterine device (IUD) inserted immediately post-abortion
Study: NCT01640873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8655
Description: Participants will receive MK-8655 as a single dose on Day 1. Participants will receive MK-8655, once a day (q.d.), for 14 consecutive days (Day 3 through Day 16). MK-8655 doses may be adjusted downward based on the results of ongoing studies.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Placebo as a single dose on Day 1. Participants will receive Placebo, q.d., for 14 consecutive days (Day 3 through Day 16).
Study: NCT02372591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
Study: NCT03787654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: BL33 and BL35 are inserted by needles of 0.30×75mm size till a depth of 60\~70mm. SP6 is inserted by needle of 0.30×40mm size till a depth of 25-30mm. After manipulation and deqi sensation generation, the electrodes will be attached to the acupoints transversely with 20Hz continuous wave and an electricity current of 2mA-6.5mA at BL33 and BL35, and 1-3.5mA at SP6. The current is adjusted from zero to the degree where patients can tolerate.~Subjects receive 3 sessions per week（every other day ideally) for 12 weeks, 36 sessions in total.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham electroacupuncture
Description: In sham electroacupuncture group, sham acupoints 1 cun(≈15mm） horizontally outwardly lateral to BL33 and BL35, and 0.5 cun (≈10mm) horizontally behind SP6 are stimulated by needles of 0.30×40mm size. The needles are inserted to a depth of 2-3mm to stand still, without any manipulation and sensation of deqi. The electrodes will also be attached to needles with an electricity current of 0.1-0.3mA.~The sessions will be the same as the electroacupuncture group.
Study: NCT02372591

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
Study: NCT03240393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: cMET GCN ≥ 6 cMET GCN ≥ 4 and \< 6 cMET mutations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: cMET GCN ≥ 6 cMET GCN ≥ 4 and \< 6 cMET mutations
Study: NCT03844789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: t:slim X2 with Control-IQ Technology & Dexcom G6 CGM
Description: Eligible participants will be use the t:slim X2 with Control-IQ Technology \& Dexcom G6 CGM technology for 16 weeks during the main study. All participants will be provided the option of continue using the t:slim X2 with Control-IQ system in a 12 week Extension Phase. This arm to be uset:slim X2 with Control-IQ Technology \& Dexcom G6 CGM

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Eligible participants will be use the study Dexcom G6 CGM for 16 weeks during the main study. All participants will be provided the option of using the t:slim X2 with Control-IQ system in a 12 week Extension Phase.
Study: NCT02658916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB092
Description: Same dose as corresponding CN002003 study panel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB092
Description: Same dose as corresponding CN002003 study panel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB092
Description: Same dose as corresponding CN002003 study panel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB092
Description: Same dose as corresponding CN002003 study panel.
Study: NCT02948920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: 9 mg of ephedrine (3 ml)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NSS
Description: 3 ml of normal saline
Study: NCT03472092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: This intervention will consist of 8 weekly sessions. The duration of each session is about 45 minutes and will be led by a psychologist/therapist using a manualized protocol. About half of the sessions will be conducted in person and the remaining sessions will be offered via telehealth (Skype or phone).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo pill will be administered once a day at home for 8 weeks, to be taken by mouth with or without food under the supervision of the participant's parent or guardian. To maintain blinding, all participants will receive 1 matching capsule as a daily dose to be taken each evening during the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: Amitriptyline will be administered once a day at home for 8 weeks, to be taken by mouth with or without food under the supervision of the participant's parent or guardian. To maintain blinding, all participants will receive 1 matching capsule as a daily dose to be taken each evening during the study. For this study, a dose of 0.25 mg/kg/day will be provided for the 1st 2 weeks, followed by a dose of 0.5 mg/kg/day for 2 weeks, 0.75 mg/kg/day for 2 weeks and a maximum dose of 1.0 mg/kg/day for 2 weeks based on tolerability. Participants experiencing tolerability issues, may be held a current dose rather than titrated to the next dosage if deemed appropriate by the study doctor.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback-Assisted Relaxation Training (BART)
Description: This intervention will consist of 8 weekly sessions. The duration of each session is about 45 minutes and will be led by a psychologist/therapist using a manualized protocol. About half of the sessions will be conducted in person and the remaining sessions will be offered via telehealth (Skype or phone).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Reappraisal Training (CR)
Description: This intervention will consist of 8 weekly sessions. The duration of each session is about 45 minutes and will be led by a psychologist/therapist using a manualized protocol. About half of the sessions will be conducted in person and the remaining sessions will be offered via telehealth (Skype or phone).
Study: NCT01352533

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcuticular polyglactin-910 combined with tissue adhesive
Description: Approximately half of the experimental wounds will be randomized to be closed with a combination of subcuticular polyglactin-910 and tissue adhesive.
Study: NCT01525446

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT with proton beam radiation
Description: 4 consecutive days for the delivery of 48 Gy (tumors 3 cm or less) or 5 consecutive days for the delivery of 60 Gy (tumors of \> 3 cm)
Study: NCT03240393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: cMET GCN ≥ 6 cMET GCN ≥ 4 and \< 6 cMET mutations
Study: NCT04583306

Intervention type: OTHER
Intervention: Raman analysis of saliva, characterization of the Raman database and building of the classification model
Description: Saliva will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.

Intervention type: OTHER
Intervention: Raman analysis of saliva, characterization of the Raman database and building of the classification model
Description: Saliva will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.

Intervention type: OTHER
Intervention: Raman analysis of saliva, characterization of the Raman database and building of the classification model
Description: Saliva will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.
Study: NCT01495663

Intervention type: DRUG
Group type: OTHER
Intervention: I-131-CLR1404
Description: Description:~* Dosimetry: IV, 5 mCi, single dose, 6-day duration~* Therapy: IV, starting dose level of 12.5 mCi/m2, single dose, 56-day duration with follow up to one year
Study: NCT01197807

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bulb Suctioning
Description: Bulb suctioning of the mouth then the nose immediately following delivery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wiping
Description: Gentle wiping of mouth then nose with a soft cloth immediately following delivery
Study: NCT03197090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenicor ECG
Description: Participants will place their thumbs on the device twice daily and whenever they notice palpitations.
Study: NCT02731885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464 Single dose
Description: Two-periods, subjects received a single dose of 50mg of ABX464 in fed and fasted condition, separated by a wash-out period of at least 45 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464 Single dose
Description: Two-periods, subjects received a single dose of 50mg of ABX464 in fed and fasted condition, separated by a wash-out period of at least 45 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464 Repeated dose
Description: Subjects received 50mg of ABX464 every 3 days during 10 days in fasted or fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464 Repeated dose
Description: Subjects received 50mg of ABX464 every 3 days during 10 days in fasted or fed condition.
Study: NCT00281424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pedometer
Description: gave pedometer and info
Study: NCT02958397

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD33-CAR-transduced T cells
Description: The first 3 enrolled patients will receive autologous-derived CD33-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
Study: NCT02635152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpretation Bias Modification
Description: Eight 10-25 minute sessions of interpretation modification to reduce negative interpretation biases related to appearance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation
Description: Eight 15-minute sessions of progressive muscle relaxation (PMR).
Study: NCT00839371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: i.v. propofol titration until adequate depth of sedation
Study: NCT00434122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix mid-luteal, 2.5 mg
Description: Degarelix 2.5 mg will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak and on Stimulation Day 6. Placebo will be injected SC on Stimulation Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak. Degarelix 2.5 mg will be injected SC on Stimulation Day 1 and Stimulation Day 6.~or Placebo will be injected SC 7 days after LH peak and on Stimulation Day 1. Ganirelix 0.25 mg will be injected SC daily from Stimulation Day 6 until the last stimulation day.
Study: NCT05341674

Intervention type: OTHER
Intervention: the stumps of all patients were scanned with the Artec Eva Lite brand 3D scanner.
Description: the stumps of all patients were scanned with the Artec Eva Lite brand 3D scanner.
Study: NCT00536042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: addition of 150 mg to 250 mg po bid to standard asthma care regiment
Study: NCT00839371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: i.v. midazolam titration until adequate depth of sedation
Study: NCT01091831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be given orally at the dose of 300 mg/m2 on days 1, 8, 15 for 6 cycles every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide will be given orally at the dose of 25 mg/d for 21 days followed by a 7 days rest period (day 22 to 28)for 6 cycles every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 for 6 cycles every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Melphalan will be given iv at the dose of 200 mg/m2 for 1 day followed by stem cell support. The second MEL200 was performed 120 days after the first if ≤ PR was achieved after the 1st MEL200.
Study: NCT03158025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant tablets
Description: Lemborexant 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant tablets
Description: Lemborexant 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant tablets
Description: Lemborexant 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant tablets
Description: Lemborexant 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant tablets
Description: Lemborexant 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo lemborexant
Description: Placebo 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg lemborexant tablets will be administered orally.